1 / 80

Atrial Fibrillation: Key Concepts

Atrial Fibrillation: Key Concepts. Dr. Dave Dyck R3 April 10/2003. Today’s Objectives:. Review some of the landmark papers on rate vs rhythm control in detail. Review the literature on a few questions I had one day on atrial fibrillation: Why 48 hours? Use of TEE

thetis
Télécharger la présentation

Atrial Fibrillation: Key Concepts

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Atrial Fibrillation: Key Concepts Dr. Dave Dyck R3 April 10/2003

  2. Today’s Objectives: • Review some of the landmarkpapers onrate vs rhythm control in detail. • Review the literature on a few questions I had one day on atrial fibrillation: • Why 48 hours? • Use of TEE • “Lone” atrial fibrillation • Low Molecular Weight Heparin in atrial fibrillation • +++ Discussion/Questions at the end • (Will not discuss antiarrhythmics and no epidemiology, pathophysiology, etc.)

  3. Rate vs Rhythm • Historically goal of treatment has been maintenance of sinus rhythm. • Majority of trials in the literature are on anti-arrhythmics looking at conversion/maintenance of sinus rhythm as the primary outcome • Recent literature is providing good evidence that for most cases rate control is equal to, and possibly better than, rhythm control

  4. 3 papers to know: • PIAF • Recurrent Persistent Atrial Fibrillation • AFFIRM (landmark paper)

  5. “Hot Café” Study: • Initial randomized attempt to look at rate vs. rhyhm control in non-valvular chronic a fib. • Small prospective Polish study (plan to include 200 pts) • No final results published • Opolski et. al. in Polskie Archiwum Medycyny Wewnetrznej. 101(5):413-8, 1999, May

  6. Pharmacological Intervention in Atrial Fibrillation (PIAF) trial: • Hohnloser S.H, Kuck K.H., and Lilienthal J. Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000; 356: 1789-94 • Open randomized trial at 21 German sites • Inclusion criteria: • Symptomatic persistent atrial fibrillation (7-360d) • Ages 18-75

  7. Exclusion Criteria: • CHF NYHA class IV • Unstable angina or acute MI within 30d • HR<50bpm • Sick sinus syndrome • Accessory pathway (WPW) • CABG/Valve repair within 3 months • Hypertrophic cardiomyopathy • Amiodarone tx within 6 months • Acute thyroid disease • Pacemaker • Pregnancy • CI to anticoagulants

  8. Methods: • Group A (Rate control) = diltiazem 90 mg bid or tid +/- additional rate control therapy at discretion of MD • Group B (Rhythm control) = amiodarone 600mg od x 3 weeks +/- electrical cardioversion + amiodarone 200mg od • All patients anticoagulated (INR 2-3)

  9. Primary Endpoints: Change from baseline in the 3 most reported a fib symptoms: - palpitations - dyspnea - dizziness

  10. Secondary Endpoints: • Ease of fatiguability (6min walking tests) • Change in mean HR • Stabilization of sinus rhythm • # hospital admissions • Quality of Life questionnaire. (SF-36)

  11. Trial Profile:

  12. Baseline Characteristics:

  13. Intention To Treat Analysis:* • Results:

  14. Secondary Endpoints:*

  15. Summary: • 1st good randomized trial showing no difference between improvement of symptoms due to a fib in a rate vs rhythm treatment strategy • (BUT – No Mortality End-points)

  16. Recurrent Persistent Atrial Fibrillation Trial (RACE): • Van Gelder et. Al. A Comparison of Rate Control and Rhythm Control in Patients with Recurrent Persistent Atrial Fibrillation. New England Journal of Medicine 347 (23): 1834-1840. December 5, 2002. • Multicentered Randomized Dutch Trial • N=522 • Inclusion Criteria: • Recurrent persistent A fib or flutter <1 year • 1 or 2 electrical cardioversions within 2 years

  17. Exclusion Criteria: • CHF NYHA class IV • Current/previous amiodarone treatment • pacemaker

  18. Rate control: • Use of digoxin, Ca channel blocker, and B-blocker alone or in combination • Target HR<100 • Cardioversion or AV node ablation + pacemaker if intolerable symptoms

  19. Rhythm Control • Electrical cardioversion without antiarrhythmic pretreatment then sotalol 160-320mg od • If recurrence within 6 months DC cardioversion + flecainide or propafenone  if recurrance  amiodarone + DC cardioversion • If recurrence after 6 months of any treatment above  no changes

  20. Methods Cont. • All anticoagulated 4 weeks prior and post cardioversion (goal INR 2.5-3.5) • If NSR at 1 month  ASA or no anticoag. • ASA allowed in rate control group if <65 and no cardiac disease (o/w anticoag.)

  21. Primary End Point* • Composite of death from cardiovascular causes, heart failure, thromboembolic complications, bleeding, pacemaker need, or severe adverse antiarrhythmic drug effects • Over 3 years of maximum follow-up

  22. Baseline characteristics: • Only statistically significant difference was more hypertension in rhythm control group (p.007)

  23. Outcome:*

  24. Summary: • No advantage to rhythm control vs rate control in recurrent persistent a fib. (trend in favor of rate control which was almost significant) • (esp. HT & women on POST-HOC analysis)* • (note – not applicable to 1st time a fib pts)

  25. AFFIRM trial: • Wyse DG et al, A Comparison of Rate Control and Rhythm Control in Patients with Atrial Fibrillation (AFFIRM investigators), New England Journal of Medicine, 347 (23), 1825-1833, December 5, 2002. • Multicentered Randomized North American Trial • N=4060

  26. Inclusion Criteria: • A fib which was likely to be recurrent and cause illness or death • Age >65 or other CVA/death risk factors • Expected long term treatment • Anticoagulation not contraindicated • Eligible to undergo trials of at least 2 drugs in both treatment strategies

  27. Rate Control: • Goal HR < 80 bpm at rest and < 110 bpm during 6 min walk test • Options: beta blockers, Ca channel blockers, digoxin (alone or in combination) • Anticoagulated INR=2.0-3.0

  28. Rhythm Control: • Antiarrhythmic chosen by treating physician (amiodarone, disopyramide, dofetilide, flecainide, moricizine, procainamide, propafenone, quinidine, sotalol, and combinations allowed) • Anticoagulation encouraged but could be dc’d if NSR at 4, or preferably, 12 weeks if the physician chose to

  29. Other considerations: • If 2 trials of either a rate or rhythm control drug failed, then non-pharmacologic therapies could be considered (ablation, maze procedure, pacing etc)

  30. Primary End Point: • Overall mortality

  31. Secondary End Points: • Composite of death, disabling stroke, disabling anoxic encephalopathy, major bleeding, and cardiac arrest. • Mean follow-up time of 3.5 years

  32. Of Note:* • More than 1/3 were enrolled after having had a first episode of a fib* • More than 2/3 had duration > 2 days • No significant differences in baseline characteristics • Only 12% had no associated cardiac disease (may not apply well to lone a fib) • 7401 patients were eligible and offered enrollment, but only 4060 were enrolled**

  33. Drugs Used:*

  34. Rate control f/u: • At 5 year visit: 34.6% in NSR, and over 80% in a fib had adequate HR control. 5% had radiofrequency ablation. • 248/2027 crossed over to rhythm control at some point with 86 of these returning to rate control by the end of the study. (uncontrolled a fib/CHF were most common reasons)

  35. Rhythm Control f/u: • At 5 year visit: 62.6% in NSR. Electrical cardioversion attempted x1 (18%), x2 (11%), x3 or more (9%) • 594/2033 crossed over to rate control at some point with 61 returning to rhythm control by the end (inability to maintain NSR and drug intolerance)

  36. Results:* • Intention to treat analysis

  37. No significant difference between rate control (21.3%) vs rhythm control (23.8%) and a trend towards benefit of rate control p=.08*

  38. Secondary End Points:*

  39. Summary: • LANDMARK PAPER! • There is no benefit to rhythm control over rate control in patients > 65 or with other stroke risk factors who have persistent/recurrent atrial fibrillation. In these patients there is even a trend towards benefit of rate control. • This is also one of the first trials to show that in first presentation a fib, if selected as likely to be recurrent/persistent and mandate treatment, then there is also a trend to benefit of rate control. • Does not apply to lone a fib; especially in the younger population*

  40. Question 2: Why 48 hrs?

  41. Risks of Thromboembolism with Cardioversion: Why 48 hrs? • Weigner et. Al. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Annals of Internal Medicine Vol 126 (8); April 15,1997. • Prospective chart review of admitted patients with atrial fibrillation clinically estimated to be < 48 hrs in duration. • Outcome= thromboembolic events during hospitalization or within 30 days of conversion • (excluded those who were therapeutically anticoagulated on presentation)

  42. Results: • 375 patients (mean age 68 +/- 16 yrs)* • 357 (95.2%) patients converted to NSR (250 spontaneously and 107 actively converted) • 228 (61%) patients were anticoagulated or given ASA upon admission (IV heparin= 133; 35.5%, coumadin= 26; 6.9%, ASA= 69; 18.4%) • 3 patients (0.8%) (95% CI=.2-2.4%) had clinical thromboembolic events (This is the same rate as for patients >48 hrs treated with the conventional coumadin for 4 weeks pre/post conversion)**

  43. Affected patients: • 1. 86y female w HTN (on ASA) with 24 hrs a fib converted spontaneously to NSR with rate control and had a L parietal embolic stroke <12 hrs later (pt was not anticoagulated) • 2. 83y female w CAD and a fib < 24 hrs on presentation converted with rate control after 2 days and heparin was DC’d. The next day she had a brachial artery embolus. • 3. 89y female w HTN and a fib < 24 hrs converted to NSR with rate control the next day (<48hrs). 12 hrs post conversion the patient became aphasic which then resolved within hours. (pt was not anticoagulated until after her TIA) • (2 of these patients did not have anticoagulants started)*

  44. Summary: • This study provides fairly good evidence that the risk of thromboembolism after cardioversion of AF<48 hrs is low. • (This study also recommended that IV heparin be initiated on admission for all patients with AF < 48 hours, and continued for at least 24 hours post cardioversion.)

  45. More Evidence: • Gallagher MM et al. Embolic complications of direct current cardioversion of atrial arrhythmias: Association with low intensity of anticoagulation at the time of cardioversion. Journal of the American College of Cardiology. 40(5): 926-33, 2002 Sep 4. • DC cardioversion performed within 2 days of onset of AF/flutter in 443 episodes (352 pts not on prolonged anticoagulation) • 1 embolic event

  46. More evidence: • Mitchell et. al., Cardioversion related stroke rates in atrial fibrillation and atrial flutter, Circulation, 1997; 96:I-453. • Reviewed the Ibutilide database to review the cardioversion related (<7d) stroke rate in patients who were cardioverted at <48 hrs and not given prolonged anticoagulation • In 688 patients 1 stroke occurred.**

  47. Summary: • Reasonable evidence that there is a very low risk of thromboembolism if cardioversion occurs in atrial fibrillation < 48 hrs duration.*

More Related